Log in
(Ad)
In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

NYSE:ABT - Abbott Laboratories Stock Price, Forecast & News

$91.86
+2.13 (+2.37 %)
(As of 01/23/2020 03:37 AM ET)
Today's Range
$90.03
Now: $91.86
$92.45
50-Day Range
$84.02
MA: $86.69
$91.86
52-Week Range
$68.80
Now: $91.86
$92.45
Volume9.84 million shs
Average Volume5.92 million shs
Market Capitalization$162.45 billion
P/E Ratio49.92
Dividend Yield1.60%
Beta1.12
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP00282410
CIK1800
Phone224-667-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.58 billion
Cash Flow$4.96 per share
Book Value$17.49 per share

Profitability

Net Income$2.37 billion

Miscellaneous

Employees103,000
Outstanding Shares1,768,456,000
Market Cap$162.45 billion
Next Earnings DateN/A
OptionableOptionable

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

George Gilder has a shocking message for anybody with money in the bank, with a job that pays in dollars, or who carries a smartphone in their pocket. "Brace yourself," he says, "for the coming $16.8 trillion global 'reboot' ahead." It could change the way you get paid...change the way you save and invest for retirement.

Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories announced a quarterly dividend on Friday, December 13th. Shareholders of record on Wednesday, January 15th will be given a dividend of $0.36 per share on Friday, February 14th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 1.57%. The ex-dividend date of this dividend is Tuesday, January 14th. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.32. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) released its earnings results on Wednesday, January, 22nd. The healthcare product maker reported $0.95 earnings per share for the quarter, meeting the consensus estimate of $0.95. The healthcare product maker had revenue of $8.31 billion for the quarter, compared to the consensus estimate of $8.26 billion. Abbott Laboratories had a net margin of 10.50% and a return on equity of 17.65%. Abbott Laboratories's revenue was up 7.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.81 earnings per share. View Abbott Laboratories' Earnings History.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its FY20 earnings guidance on Wednesday, January, 22nd. The company provided earnings per share (EPS) guidance of $3.55-3.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.60.

What price target have analysts set for ABT?

16 analysts have issued 1 year price objectives for Abbott Laboratories' shares. Their forecasts range from $81.00 to $101.00. On average, they anticipate Abbott Laboratories' share price to reach $91.27 in the next twelve months. This suggests that the stock has a possible downside of 0.6%. View Analyst Price Targets for Abbott Laboratories.

What is the consensus analysts' recommendation for Abbott Laboratories?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 2 sell ratings, 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

Has Abbott Laboratories been receiving favorable news coverage?

Media stories about ABT stock have trended negative on Thursday, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Abbott Laboratories earned a news impact score of -2.4 on InfoTrie's scale. They also assigned media stories about the healthcare product maker a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Abbott Laboratories.

Who are some of Abbott Laboratories' key competitors?

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Walt Disney (DIS), Home Depot (HD), NVIDIA (NVDA), Pfizer (PFE), Intel (INTC) and Micron Technology (MU).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:
  • Mr. Miles D. White M.B.A., Chairman & CEO (Age 64)
  • Mr. Robert B. Ford, Pres & COO (Age 45)
  • Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
  • Mr. Stephen R. Fussell, Exec. VP of HR (Age 62)

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.11%), Gateway Investment Advisers LLC (0.05%), Hexavest Inc. (0.04%), Nisa Investment Advisors LLC (0.04%), Zurcher Kantonalbank Zurich Cantonalbank (0.04%) and Candriam Luxembourg S.C.A. (0.04%). Company insiders that own Abbott Laboratories stock include Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Which institutional investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Norris Perne & French LLP MI, OLD National Bancorp IN, Artemis Investment Management LLP, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Candriam Luxembourg S.C.A., Huntington National Bank and Hexavest Inc.. Company insiders that have sold Abbott Laboratories company stock in the last year include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Which institutional investors are buying Abbott Laboratories stock?

ABT stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Garnet Equity Capital Holdings Inc., Janney Montgomery Scott LLC, Rockland Trust Co., United Services Automobile Association, Donaldson Capital Management LLC, United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund and Advisors Capital Management LLC. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks, John G Stratton and Randel William Woodgrift. View Insider Buying and Selling for Abbott Laboratories.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $91.86.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $162.45 billion and generates $30.58 billion in revenue each year. The healthcare product maker earns $2.37 billion in net income (profit) each year or $2.88 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.View Additional Information About Abbott Laboratories.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is http://www.abbott.com/.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.


MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  779 (Vote Outperform)
Underperform Votes:  650 (Vote Underperform)
Total Votes:  1,429
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel